Subscribe to the Doherty Institute mailing list for the latest news, events and research
Latest News
Upcoming Events
-
29 Nov 2019
World Aids Day 2019 - save-the-date
-
02 Dec 2019
Introductory course in applied microbial genomics for public health and antimicrobial resistance
Stay tuned for more events to be announced soon
Latest Work
Emerging Infections
Environmental surveillance for poliovirus
The lab tests sewage collected at sentinel sites in Australia - even negative results for poliovirus are of international significance in the fight to eradicate polio.
HIV
Examining HIV incidence in Victoria
The Nicholson group are involved in a collaborative project which aims to assess whether the introduction of PrepX in 2016 has reduced HIV incidence in Victoria.
Antimicrobial Resistance and Healthcare Associated Infections
Investigating hospital superbugs
The Stinear group is investigating the molecular basis for the increasing resistance of Staphylococcus aureaus and Enterococcus to antibiotics, and also their resistance to the cleaning agents commonly used to disinfect health care facilities.
Education
Doherty Institute Student Research Opportunities. Click here to learn more.
Venue hire
The Doherty Institute has a range of spaces available for hire that can cater for meetings, seminars and other larger events.
Support us
Breakthroughs happen when research leaders work with philanthropists to solve difficult and pressing global health problems.
Meet Dr Lukasz Kedzierski. A Senior Research Fellow in the Fazakerley Group, Lukasz is researching immune mechanisms that lead to viral persistance in the central nervous system.
Meet Jennifer MacLachlan. Jennifer is an epidemiologist with the WHO Collaborating Centre for Viral Hepatitis and an Honorary Lecturer with the Department of Medicine. She leads the National Viral Hepatitis Mapping Project, which estimates the burden of disease and access to treatment and care for hepatitis B and C across Australia, and guides the measurement of Australia’s strategic response to viral hepatitis.
Joint Venture Partners
